Table 2.
The most frequent moderately-late side effects recorded
|
Moderately-late side effects | ||||||||
|---|---|---|---|---|---|---|---|---|
| Adverse events | Grade |
Baseline |
3 months |
6 months |
12 months |
18 months |
24 months |
30 months |
| 30 pts | 30 pts | 30 pts | 29 pts | 28 pts | 27 pts | 26 pts | ||
|
Erythema pigmentation |
Grade 0 |
|
6 |
14 |
18 |
22 |
23 |
22 |
|
Grade1 |
|
23 |
16 |
11 |
6 |
4 |
4 |
|
|
Grade2 |
|
1 |
0 |
0 |
0 |
0 |
0 |
|
|
Induration fibrosis |
Grade 0 |
|
23 |
23 |
22 |
24 |
23 |
22 |
|
Grade 1 |
|
6 |
6 |
7 |
4 |
4 |
4 |
|
|
Grade 2 |
|
1 |
1 |
0 |
0 |
0 |
0 |
|
|
Telangiectasia |
Grade 0 |
|
30 |
30 |
29 |
26 |
23 |
21 |
| |
Grade 1 |
|
0 |
0 |
0 |
2 |
4 |
4 |
| |
Grade 2 |
|
0 |
0 |
0 |
0 |
0 |
1 |
|
Breast/chest wall pain |
Grade 0 |
23 |
13 |
16 |
17 |
18 |
20 |
20 |
|
Grade 1 |
6 |
16 |
13 |
12 |
9 |
6 |
6 |
|
|
Grade 2 |
1 |
0 |
1 |
0 |
1 |
1 |
0 |
|
|
Grade 3 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
|
|
Cough/dyspnea |
Grade 0 |
27 |
28 |
28 |
26 |
25 |
26 |
26 |
|
Grade 1 |
3 |
2 |
2 |
3 |
2 |
1 |
0 |
|
| MSK upper limb treated/neurosensitive symptoms |
Grade 0 |
18 |
24 |
25 |
25 |
25 |
25 |
26 |
|
Grade 1 |
10 |
5 |
4 |
4 |
3 |
3 |
1 |
|
| Grade 2 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | |
The only grade 2 reported at 30 months is a cosmetic one. Note that the number of grade 1 toxicity is low at 30 months, with significant decreased number over time for pain and skin erythema/pigmentation.
We can note that the number of grade 1 or 2 side effects for cough/dyspnea and neuro-muscular symptoms are not very significantly different between baseline and early follow-up assessments.
MSK: musculoskeletal.